NUVB heads into the final days of September with a sharp contradiction at its core: short sellers have added aggressively to positions over the past week, yet the analyst community just received a fresh endorsement from Citigroup, and options traders are notably less defensive than they have been all month.
Short interest is the dominant story this week. Shorts rebuilt meaningfully, with SI climbing to 17.2% of the free float after a jump of nearly 9.5% in shares shorted over the week. The move is concentrated in a narrow window: positions rose sharply around September 23, lifting the short count from roughly 53.9 million shares to above 58.9 million in just two sessions. That puts short interest close to the highest levels seen across the 30-day history in the dataset. Despite all this, the borrow market is far from stressed. Cost to borrow is only 0.52%, barely above its recent range, and availability has actually eased from around 97% to 103% over the week, meaning there are roughly as many shares available to lend as are already lent out. Shorts are building, but they are doing so cheaply and with plenty of room to add more. The ORTEX short score has drifted up to 78.9, a new recent high, reinforcing that the aggregate signal leans bearish, though not yet at an extreme that would flag a squeeze setup.
Options traders are telling a different story. The put/call ratio has dropped to 0.42, nearly 1.6 standard deviations below its 20-day average of 0.52, and sits at a notably call-heavy position relative to the past year. Through September, the PCR has fallen steadily from above 0.55 to its current level, a consistent shift toward calls even as the stock has given up 7.9% on the week and 15.6% over the past month to close at $5.62. That divergence, shorts adding while options buyers lean bullish, is the clearest signal of a market genuinely split on direction.
The Street is firmly in the bull camp. Citigroup initiated coverage today with a Buy rating and a $12 target, which is the most notable fresh action in the analyst record. JPMorgan started with an Overweight at $13 in August, and multiple firms including Wedbush, Citizens, and RBC maintain outperform-equivalent ratings. The consensus is buy across all seven covering analysts, with a mean target around $13, implying more than 130% upside from the current price. The bull case rests on Ibtrozi (taletrectinib), which received FDA approval in mid-2025 for ROS1+ non-small cell lung cancer and has built net US product revenue from $7.7 million in Q3 2025 to $23.2 million in Q2 2026, with first-line patient starts stabilising around 30% of new diagnoses. The bear case centres on the commercial ceiling: roughly 3,000 newly diagnosed ROS1+ NSCLC patients per year in the US is a small pool, adverse events are accumulating in an expanding safety database of 532 patients, and a competing first-line option could be approved around mid-2027. Factor scores add texture: the EPS surprise rank at the 86th percentile speaks to a company consistently beating low expectations, but EPS momentum scores rank in the bottom decile over both 30 and 90 days, and the short score rank sits at just the 4th percentile of the universe.
Institutional ownership shows some interesting directional signals within a stable top-holder base. BlackRock added 2.5 million shares as of August, bringing its stake to around 7.9% of shares. Vanguard added 477,000 shares in the same period. American Century took the largest proportional step, adding 2.18 million shares as of June 30. Founder David Hung remains the single largest holder at 17.2% of shares, though his last reported holding date is June 2025. On the insider side, all recent open-market activity recorded in the 90-day window is option exercise and plan-driven sales by the CSO, CPO, and CFO, all under pre-arranged 10b5-1 plans. Net insider flow over 90 days is negative at roughly 311,000 shares and $2 million in value, but planned-sale programmes carry far less signal than discretionary transactions. On the retail attention front, the ORTEX alt data layer flags a Wikipedia-based retail attention z-score of 2.9, a two-standard-deviation reading against the prior 90 days, suggesting the stock is drawing more individual investor interest than usual heading into the quarter-end.
Earnings are due November 2, with 33 days remaining. The last print in August produced a 3.6% one-day gain that faded to a 4.2% five-day loss, while the prior event delivered a 5.1% one-day decline. The next print will therefore be watched primarily for the trajectory of Ibtrozi revenue growth and any update on first-line market share, against a backdrop where shorts are freshly rebuilt and analysts are freshly initiated at prices well above where the stock trades today.
See the live data behind this article on ORTEX.
Open NUVB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
